Anti-CD20 CAR-T cell therapy (Wuhan Bio-Raid)

靶向CD22嵌合抗原受体T细胞疗法（武汉波睿达生物）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD20 CAR-T cell therapy (Wuhan Bio-Raid)
Drug Alias Name抗CD20 CAR-T细胞疗法-武汉波睿达生物科技有限公司Anti-CD20 chimeric antigen receptor T-cell therapy
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesWuhan BioRaid Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuhan BioRaid Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A